311 related articles for article (PubMed ID: 17227642)
1. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan.
Koong SL; Yen AM; Chen TH
J Med Screen; 2006; 13 Suppl 1():S44-7. PubMed ID: 17227642
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
[TBL] [Abstract][Full Text] [Related]
3. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
Hristova L; Hakama M
Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests.
Kulasingam SL; Myers ER; Lawson HW; McConnell KJ; Kerlikowske K; Melnikow J; Washington AE; Sawaya GF
Obstet Gynecol; 2006 Feb; 107(2 Pt 1):321-8. PubMed ID: 16449119
[TBL] [Abstract][Full Text] [Related]
5. High-grade cervical abnormalities and screening intervals in New South Wales, Australia.
Schindeler S; Morrell S; Zuo Y; Baker D
J Med Screen; 2008; 15(1):36-43. PubMed ID: 18416954
[TBL] [Abstract][Full Text] [Related]
6. Cervical cancer screening program of Paraná: cost-effective model in a developing country.
Bleggi Torres LF; Werner B; Totsugui J; Collaço LM; Araújo SR; Huçulak M; Boza EJ; Fischer RM; De Laat L; Sobbania LC; Raggio A
Diagn Cytopathol; 2003 Jul; 29(1):49-54. PubMed ID: 12827718
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.
Kim JJ; Leung GM; Woo PP; Goldie SJ
J Public Health (Oxf); 2004 Jun; 26(2):130-7. PubMed ID: 15284314
[TBL] [Abstract][Full Text] [Related]
8. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
Suba EJ; Nguyen CH; Nguyen BD; Raab SS;
Cancer; 2001 Mar; 91(5):928-39. PubMed ID: 11251944
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range?
Anderson R; Haas M; Shanahan M
Aust N Z J Public Health; 2008 Feb; 32(1):43-52. PubMed ID: 18290913
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
[TBL] [Abstract][Full Text] [Related]
11. Clinical and cost implications of new technologies for cervical cancer screening: the impact of test sensitivity.
Hutchinson ML; Berger BM; Farber FL
Am J Manag Care; 2000 Jul; 6(7):766-80. PubMed ID: 11067374
[TBL] [Abstract][Full Text] [Related]
12. Effect of an antepartum Pap smear on the coverage of a cervical cancer screening programme: a population-based prospective study.
Nygård M; Daltveit AK; Thoresen SO; Nygård JF
BMC Health Serv Res; 2007 Jan; 7():10. PubMed ID: 17244348
[TBL] [Abstract][Full Text] [Related]
13. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden.
Andrae B; Kemetli L; Sparén P; Silfverdal L; Strander B; Ryd W; Dillner J; Törnberg S
J Natl Cancer Inst; 2008 May; 100(9):622-9. PubMed ID: 18445828
[TBL] [Abstract][Full Text] [Related]
14. Papanicolaou smear screening of women with intellectual disabilities: a cross-sectional survey in Taiwan.
Lin LP; Lin JD; Sung CL; Liu TW; Liu YL; Chen LM; Chu CM
Res Dev Disabil; 2010; 31(2):403-9. PubMed ID: 19897337
[TBL] [Abstract][Full Text] [Related]
15. Effective cervical cytology screening programmes in middle-income countries: the Chilean experience.
Sepúlveda C; Prado R
Cancer Detect Prev; 2005; 29(5):405-11. PubMed ID: 16188399
[TBL] [Abstract][Full Text] [Related]
16. Evolution of multiple disease screening in Keelung: a model for community involvement in health interventions?
Wang PE; Wang TT; Chiu YH; Yen AM; Chen TH
J Med Screen; 2006; 13 Suppl 1():S54-8. PubMed ID: 17227644
[TBL] [Abstract][Full Text] [Related]
17. Colorectal cancer screening with faecal occult blood test within a multiple disease screening programme: an experience from Keelung, Taiwan.
Yang KC; Liao CS; Chiu YH; Yen AM; Chen TH
J Med Screen; 2006; 13 Suppl 1():S8-13. PubMed ID: 17227635
[TBL] [Abstract][Full Text] [Related]
18. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
Ginsberg GM; Edejer TT; Lauer JA; Sepulveda C
Vaccine; 2009 Oct; 27(43):6060-79. PubMed ID: 19647813
[TBL] [Abstract][Full Text] [Related]
19. Report from the CDC. Pap test intervals used by physicians serving low-income women through the National Breast and Cervical Cancer Early Detection Program.
Cooper CP; Saraiya M; McLean TA; Hannan J; Liesmann JM; Rose SW; Lawson HW
J Womens Health (Larchmt); 2005 Oct; 14(8):670-8. PubMed ID: 16232098
[TBL] [Abstract][Full Text] [Related]
20. Cancer screening in Singapore, with particular reference to breast, cervical and colorectal cancer screening.
Yeoh KG; Chew L; Wang SC
J Med Screen; 2006; 13 Suppl 1():S14-9. PubMed ID: 17227636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]